CD44 and neoplasm: CD44+ LAPC9 cells, however, when implanted subcutaneously or orthotopically in the dorsal prostate (DP), exhibited ∼6- and 19-fold, respectively, higher tumor-initiating potential than corresponding CD44− LAPC9 cells (Table 2).